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Metabolic/hepatic encephalopathy is neuropathologically
characterized by the presence of Alzheimer type II astro-
cytes (AA II) with large and clear nuclear morphology.
To date, there is no good immunohistochemical marker to
better identify these cells. Here, we assessed cases of
hepatic encephalopathy of different etiologies by immuno-
histochemistry using an anti-p62 antibody. We observed
peripheral or diffuse nuclear staining of variable intensity
in AA II in all cases but not in normal controls or reactive
astrocytes. We conclude that p62 is a useful immunohisto-
chemical marker for the identification of AA II and may
be helpful for the neuropathological diagnosis of meta-
bolic/hepatic encephalopathy in difficult or equivocal
cases.
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INTRODUCTION
The presence of so-called Alzheimer type II astrocytes
(AA II) in the human brain usually reflects a metabolic distur-
bance caused by renal or, more frequently, hepatic dysfunc-
tion. Indeed, hepatic encephalopathy has been associated with
the presence of AA II in the gray matter of different brain
regions, usually involving the deep cortical layers, basal gang-
lia, and pontine nuclei.1 It is, therefore, considered to reflect a
gliopathy.
AA II are characterized by a larger nucleus than in resting
or reactive fibrillary or gemistocytic astrocytes, a clear chroma-
tin (Fig. 1G), and scarce cellular processes. They are frequently
forming pairs: doublets, or even triplets1 (Fig. 1H). However,
AA II may be difficult to visualize on sections stained with
hematoxylin and eosin (HE), showing a spectrum of nuclear
changes, from slight enlargement and chromatin loosening to a
completely clear or empty appearance of the nucleus with a
well-defined membrane rim and peripheral dot-like condensa-
tion (Fig. 1I, arrow). There is currently no goodmarker to spe-
cifically identify AA II: they are characteristically not or are
poorly stained by glial fibrillary acidic protein (GFAP) immu-
nohistochemistry, while they can be depicted using anti-S-100
protein antibodies.1,2 However, S-100 protein is not a specific
marker of astrocytes and labels most glioneuronal elements.
Because the neuropathological diagnosis of metabolic enceph-
alopathy may be difficult in its early or less severe disease
stages, the application of a reliable immunohistochemical
marker would be helpful to objectively support this diagnosis
in the routine diagnostic or experimental settings.
Through staining of postmortem brains for other diagnos-
tic purposes, we observed an intense staining of AA II nuclei
using p62 immunohistochemistry in patients with metabolic
encephalopathy. This observation prompted us to systemati-
cally assess glial p62 immunoreactivity in hepatic encephalop-
athy of different etiologies and to compare the staining
pattern with other conditions characterized by prominent
reactive gliosis.
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MATERIALS AND METHODS
Postmortem brains were selected from the archives of the
Institute of Neurology of the Medical University of
Vienna and the Neurological Tissue Bank of the
IDIBAPS Biobank in Barcelona. The use of brain tissue
for research was approved by the respective institutional
ethics committees and conforms to the provisions of the
Declaration of Helsinki.
Formalin-fixed, paraffin-embedded tissue blocks from the
frontal, temporal and occipital cortices, anterior and posterior
basal ganglia, thalamus, midbrain, pons and cerebellum were
selected, and 5-μm-thick sections were stained with hematox-
ylin and eosin (HE) and Luxol fast blue (LFB) andHE (LFB-
HE), where the presence of AA II was assessed as present/
absent (Table 1). One region per case with obviousAA II was
first stained by immunohistochemistry using a commercial
Fig. 1 Microphotographs
of brain sections of hepatic
encephalopathy (A-L) and mito-
chondrial encephalopathy/Leigh
syndrome (M-O). Laminar
microvacuolation of the neuropil
in cortical layers of the cerebrum
is observed in a case of severe
hepatic encephalopathy at a low
magnification (arrows in A, B)
and at a higher magnification (D,
E). Abundant p62-positive nuclei
are identified in deep layers at a
low magnification (arrows in C)
and at a higher magnification
(F). AA II have the characteris-
tic enlarged cell nuclei and clear
chromatin (G). AA II forming a
triplet of nuclei (H). Small punc-
tate condensations along the
nuclear membrane in an AA II
(I). p62 immunohistochemistry
strongly labels the nuclei of AA
II, including the peripheral
nuclear membrane condensa-
tions (arrows in L). (M-O) In a
case of Leigh syndrome, glial
nuclei in the basal ganglia are
also enlarged but show more
prominent cytoplasm on HE sta-
ined sections than typical AA II
(M). p62 shows intense and dif-
fuse labeling of enlarged glial
nuclei (N, O). HE (A, D, E, G,
H, M), LFB-HE (B), p62 immu-
nohistochemistry (C, F, J-L, N,
O). Scale bars: 200 μm (A–C), 50
μm (N), 20 μm (D–H, J, K–M),
10 μm (I).
© 2020 The Authors. Neuropathology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of
Neuropathology.
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monoclonal anti-p62 antibody (clone 3/p62 ligand, dilution
1:500; BD-Transduction Laboratories, Franklin Lakes, NJ,
USA). Then, selected cases of hepatic diseases (Table 2) were
immunostained for p62 in the frontal cortex, basal ganglia, and
pons, and in one case, a detailed mapping of p62 distribution
was performed (Table 1). Antigen retrieval was performed by
boiling the sections in citrate buffer at pH 6.0 for 20 min. The
immunoreaction was visualized by the polymer-immuno-
complex method using an Envision System kit (Dako, Glo-
strup, Denmark), and 3,3’-diaminobenzidine was used as
chromogen. For double immunofluorescence labeling, the
anti-p62 antibody was combined with antibodies against S-100
protein (rabbit polyclonal, dilution 1:2000; Dako),GFAP (rab-
bit polyclonal, dilution 1:5000; Dako), and tubulin polymeriza-
tion-promoting protein (TPPP/p25 (rabbit polyclonal, dilution
1:2000; non-commercial). It has been shown that TPPP is
mainly expressed in differentiated oligodendrocytes of the
central nervous system (CNS),3 After blocking of
autofluorescencewith SudanBlackB, antibody binding immu-
noreactivities was visualized with secondary antibodies such as
anti-mouse IgG conjugated with Alexa Fluor488 (Thermo
Fisher Scientific, Waltham, MA, USA) at a dilution of 1:800
and anti-rabbit IgG conjugated with Cy3 (Thermo Fisher Sci-
entific) at a dilution of 1:1000.
We selected 31 cases with hepatic encephalopathy of viral
(Hepatitis C), neoplastic (hepatocarcinoma and liver metas-
tasis), alcoholic (liver cirrhosis), systemic (sepsis), and mito-
chondrial (Leigh syndrome) origins (Table 1). For additional
comparison of the immunostaining pattern, we assessed
different pathologies, including subacute stage of cerebral
infarction with prominent reactive gliosis, as well as different
neurodegenerative diseases with variable degrees of chronic
reactive gliosis, including Alzheimer’s disease, corticobasal
degeneration, progressive supranuclear palsy, Parkinson’s
disease, frontotemporal lobar degeneration with inclusions
immunoreactive for transactivation response DNA-binding
protein 43 kDa (TDP-43), and Creutzfeldt–Jakob disease
(one case each), as well as one normal brain.
Details of cases with hepatic/metabolic encephalopathy
are shown in Table 1.
RESULTS
Nuclear p62 staining was detected in enlarged glial cells of
the gray matter that were consistent with AA II on HE-
stained sections (Fig. 1J–L). This immunopositivity was
observed in all cases with hepatic encephalopathy of dif-
ferent etiologies, except for some of septic origin. Nuclear
staining for p62 in AA II was particularly intense in a case
of mitochondrial encephalopathy (Leigh syndrome)
(Fig. 1M–O). Double immunofluorescence revealed
p62-positive nuclei in some delicate GFAP-positive
(Fig. 2A) and diffuse S-100 protein-positive cells (Fig. 2B)
but not in TPPP/p25-positive oligodendrocytes (Fig. 2C),
thus supporting the astrocytic nature of the cells.
In cortical areas, AA II were best identified in deep layers.
In severely affected cases, laminar microvacuolation of the
neuropil in deep layers could be observed at a low magnifica-
tion (arrows in Fig. 1A, B) and at a higher magnification (Fig.
1D, E). Here, abundant p62-positive nuclei were identified at
a lowmagnification (arrows in Fig. 1C) and at a highermagni-
fication (Fig. 1F). When AA II showed the characteristic
enlarged nuclei with clear chromatin, immunoreactivity was
enhanced along the nuclear membrane and in the small punc-
tate condensations (Fig. 1L). In cells with less obvious nuclear
change, immunoreactivity wasmore diffuse.
The distribution and intensity of p62 immunoreactivity
in AA II nuclei was not homogeneous among different
brain areas of the same patient and between patients. The
strongest signal was generally observed in cortical areas
and was lower in the basal ganglia and pontine nuclei, but
this was not uniform (Table 2). There were cases
Table 2 p62 Immunoreactivity in the frontal cortex, basal ganglia, and pons in selected patients with different ages, etiologies, and for-
malin fixation times
Order Age Weeks in
formalin
Hepatic pathology Glial p62 nuclear immunoreactivity
Frontal cortex Basal ganglia Pons
1 79 1 Hepatitis C/cirrhosis 0/+ 1/+ 0/s
4 85 1 Alcohol abuse/cirrhosis 3/+ 3/+ 0/s
22 0,5 2 Hepatic steatosis 1/+ 2/+ 1/+
20 15 2 Sepsis, vasculitis 2/+ 0/+ 2/+
19 52 3 Sepsis 0/+ 0/+ 0/+
13 51 4 Metastasis 2/+ 2/+ 0/+
31 2 4 Mitochondrial disorder/Leigh syndrome 0/− 3/+ 2/+
14 81 > 4 Metastasis 3/+ 3/+ 0/+
7 59 6 Alcohol abuse/cirrhosis/hepatocellular carcinoma 3/+ 3/+ 2/+
11 84 6 Hepatocellular carcinoma 1/+ 0/+ 0/+
17 58 14 Acute hepatic and renal failure, B cell lymphoma 0/+ 0/+ 0/+
28 1 > 25 Cardiac malformation, hepatosplenomegaly 3/+ 0/+ 0/+
21 84 n.a. Sepsis 0/+ 0/+ 0/+
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(e.g. case 4) showing a patchy distribution of immunoreac-
tivity in the basal ganglia and cerebral cortex. In rare
cases, cells that were considered to be AA II on
HE-stained sections were not or were only faintly immu-
noreactive for p62. Inversely, some cases with p62-positive
nuclei were not always clearly identifiable as AA II: for
example, in the case of Leigh syndrome (Fig.1M–O)
where immunopositivity filled the whole nucleus, in con-
trast to other cases with peripheral nuclear immuno-
staining. Bergmann’s glia also showed relatively
prominent p62 nuclear staining in one case of metabolic
encephalopathy that had no prominent Purkinje cell loss
(case 30). In contrast, other pathologies associated with
Bergmann gliosis remained negative. Aquaporin 4 immu-
noreactivity was undetectable in AA II.
No immunostaining in glial nuclei was observed in the
control and most neurodegenerative conditions with reac-
tive astrogliosis, except for one case of corticobasal degener-
ation. In that case, p62-positive nuclei corresponded to
those of tau-positive astrocytic plaques on adjacent tissue
sections. Moreover, one case of sucacute stage cerebral
infarction showed moderate nuclear immunoreactivity of
large reactive astrocytes and also of some “eosinophilic neu-
rons.” There were no differences in staining intensity that
could be related to fixation time (Table 2) or postmortem
delay (data not shown). No data on ammonia levels were
available.
DISCUSSION
We assessed the immunohistochemical expression of p62
in glial cells in different brain diseases and observed prom-
inent nuclear staining of AA II in metabolic/hepatic
encephalopathy, including astrocytes with no typical
“clear” morphology. This was not observed in reactive
astrocytes of most chronic neurodegenerative diseases,
except for one case of corticobasal degeneration and sub-
acute stage cerebral infarction, where nuclei of astrocytic
plaques and large reactive astrocytes, respectively, were
moderately labeled.
This observation suggests p62 as a very useful neuro-
pathological marker of metabolic gliosis, particularly in
hepatic encephalopathy.
Immunohistochemistry using anti-p62 antibodies has
proved very useful in the study of neurodegenerative dis-
eases, as it is commonly found in neuronal cytoplasmic or
nuclear inclusions (e.g. Alzheimer’s disease, frontotemporal
lobar degenerations, Lewy body diseases, or trinucleotide
repeat disorders such as Huntington’s disease). The presence
of p62 is also a useful predictor of C9orf72 expansion muta-
tion when accumulated in granular neurons of the cerebellar
cortex or hippocampal neurons.4,5
p62 or sequestosome-1 is a protein encoded by
SQSTM1 and is thought to target protein aggregates for
lysosomal degradation, by binding to ubiquitinated pro-
teins, among other functions.6–8 It is, therefore, considered
to be an indicator of autophagic degradative activity. p62
itself is also degraded by autophagy. When autophagy is
induced, it remains at low levels in the cell, while it accu-
mulates when autophagy is deficient. It is also involved in
protein aggregation, as shown for several proteinopathies
associated with neurodegenerative conditions.9
Hepatic/metabolic encephalopathy has been reported to
underlie several complex metabolic alterations,10 including
mitochondrial dysfunction in astrocytes due to increased
ammonia levels in blood and in the brain,11,12 among others.
Moreover, experimental studies have shown an involvement
of mitophagy and autophagy13 in the pathogenesis of
hepatic encephalopathy. In particular, treatment of cultured
rat astrocytes with low concentrations of NH4Cl induced
autophagy, while with higher concentrations from 2 mM
onwards, NH4Cl inhibited autophagy in astrocytes in a time-
and dose-dependent manner.12 These findings may provide
one explanation for why high ammonia levels can induce the
accumulation of p62 through inhibition of autophagy. In
addition, exposure of astrocytes to ammonia also induces
Fig. 2 Microscopic findings of
double immunofluorescence
staining for p62 (green signal in
A-C) with GFAP (red signal in
A), S-100 protein (red signal in
B)m and TPPP (red signal in C).
p62 immunoreactivity is localized
in some cells with delicate
GFAP-positive branching pro-
cesses (A) and in diffusely sta-
ined S-100 protein-positive
branching processes (B). In con-
trast, they do not coincide with
TPPP-positive oligodendro-
cytes (C).
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astrocytic swelling, which can be exacerbated by cytokines/
inflammatory mediators.14 Some experimental studies have
also shown that increased plasma membrane aquaporin
4 levels contribute to the astrocytic swelling/brain edema in
hepatic encephalopathy.10 We found no increased immuno-
reactivity for aquaporin 4 in AA II. However, the detailed
mechanism of peripheral and diffuse nuclear staining for
p62 in hepatic/metabolic encephalopathy remains to be
elucidated.
We observed a somewhat uneven distribution of
p62-positive AA II within the same brain area and
between different brain areas and cases. It could be postu-
lated that this might be related to levels of ammonia
and/or duration or even to the cause of hepatic damage,
reflecting an evolutive process of metabolic alterations of
astrocytes. While it is generally considered that ammonia
levels are positively related to the severity of hepatic
encephalopathy, they are not always determinant as other
factors may exacerbate it,10,15 and they do not necessarily
influence patient management.16 Unfortunately, we do not
have enough data on ammonia levels or details on the
duration of hepatic disease. Moreover, there was no par-
ticular difference in staining intensity depending on the
etiology of liver damage, and it was apparently also not
influenced by postmortem delay or formalin fixation time.
In summary, the postmortem neuropathological diagno-
sis of metabolic/hepatic encephalopathy has been a some-
what subjective, not always unequivocal diagnosis and can
represent a challenge, particularly in less obvious stages.
Even if not absolutely specific, we consider p62 as a useful
immunohistochemical marker to visualize AA II. It can
improve and objectify the identification of metabolic
encephalopathy/gliopathy in postmortem brain tissue, in
supplementation of classical HE staining features. Why
p62 accumulates in the nucleus is, however, still unclear
and deserves further investigation, particularly to better
understand metabolic disturbances of astrocytes and their
relationship with autophagy.
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